AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11099367 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Recovery (AR) - 15 min running at 50% of VáO2max
Number of subjects: 14
Study 11099367 — intervention group
Group type: COMPARATOR
Intervention: Rest Recovery (RR) - complete rest in the supine position
Number of subjects: 14
Study 8729205 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine fumarate (1.34 mg)
Number of subjects: 150
Study 8729205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 1585845 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-Meal (25 min cycle at 60% VO2 max followed by a 902 kcal mixed meal)
Number of subjects: 6
Study 1585845 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal-Exercise (902 kcal mixed meal followed by 25 min cycle at 60% VO2 max)
Number of subjects: 6
Study 1585845 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal Only (902 kcal mixed meal)
Number of subjects: 6
Study 1585845 — intervention group
Group type: COMPARATOR
Intervention: Resting Control
Number of subjects: 6
Study 1585845 — intervention group
Group type: COMPARATOR
Intervention: Exercise Only (25 min cycle at 60% VO2 max)
Number of subjects: 6
Study 6086772 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 21
Study 6086772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 30808743 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitor+Accept
Number of subjects: 153
Study 30808743 — intervention group
Group type: COMPARATOR
Intervention: Monitor Only
Number of subjects: 153
Study 30808743 — intervention group
Group type: COMPARATOR
Intervention: Active control training
Number of subjects: 153
Study 30538086 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous remote monitoring
Number of subjects: 226
Study 30538086 — intervention group
Group type: COMPARATOR
Intervention: Intermittent monitoring alone
Number of subjects: 226
Study 26984569 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month physical exercise program, 40 minutes twice weekly for 1 year
Number of subjects: 78
Study 26984569 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month physical exercise program
Number of subjects: 78
Study 26984569 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual daily activities)
Number of subjects: 78
Study 24567651 — intervention group
Group type: COMPARATOR
Intervention: Rosemary Conley
Number of subjects: 3290
Study 24567651 — intervention group
Group type: COMPARATOR
Intervention: Slimming World
Number of subjects: 3290
Study 24567651 — intervention group
Group type: COMPARATOR
Intervention: NHS group programme
Number of subjects: 3290
Study 24567651 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Watchers
Number of subjects: 3290
Study 22025490 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wound infusion with ropivacaine 2 mg/mL at 5 mL/h for 48 hours
Number of subjects: 58
Study 22025490 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine 2 mg every 12 hours for 48 hours
Number of subjects: 58
Study 22025490 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wound infusion with ropivacaine
Number of subjects: 58
Study 20811292 — intervention group
Group type: EXPERIMENTAL
Intervention: TT homozygotes of rs2006765
Number of subjects: 1998
Study 20811292 — intervention group
Group type: COMPARATOR
Intervention: CC+CT genotype of rs2006765
Number of subjects: 1998
Study 20811292 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs4681443 of AGTR1 gene
Number of subjects: 1998
Study 18642564 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotec (Misoprostol) oral application (50 microg every 4 hours, max 200 microg)
Number of subjects: 45
Study 18642564 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotec (Misoprostol) vaginal application (two doses of 50 microg every 6 hours)
Number of subjects: 45
Study 18642564 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotec (Misoprostol) sub-lingual application (50 microg every 4 hours)
Number of subjects: 45
Study 18642564 — intervention group
Group type: COMPARATOR
Intervention: General population frequency of Sectio Caesarea
Number of subjects: 45
Study 16232069 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced version of the Incredible Years Series (n = 50)
Number of subjects: 99
Study 16232069 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control condition (n = 49)
Number of subjects: 99
Study 11157568 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with torticollis spasmodicus
Number of subjects: 0
Study 11157568 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 0
Study 9598451 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination (1.07 mg/kg mefloquine, 2.14 mg/kg sulfadoxine, 0.11 mg/kg pyrimethamine)
Number of subjects: 231
Study 9598451 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine/pyrimethamine (2.14 mg/kg sulfadoxine, 0.11 mg/kg pyrimethamine)
Number of subjects: 231
Study 9598451 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine alone (1.07 mg/kg)
Number of subjects: 231
Study 7930430 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 20
Study 7930430 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy
Number of subjects: 20
Study 7930430 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 20
Study 3280128 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden (5.0 mg)
Number of subjects: 15
Study 3280128 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (1.0 mg)
Number of subjects: 15
Study 3280128 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride (0.05 mg)
Number of subjects: 15
Study 3280128 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (2.5 mg)
Number of subjects: 15
Study 3280128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31608676 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-directed rehabilitation
Number of subjects: 42
Study 31608676 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 42
Study 30585267 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb ischemic post-conditioning (LIPOC)
Number of subjects: 16
Study 28533148 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency (20Hz) rTMS applied to the right dorsal lateral prefrontal cortex (DLPFC)
Number of subjects: 40
Study 28533148 — intervention group
Group type: COMPARATOR
Intervention: SHAM treatment
Number of subjects: 40
Study 25829103 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-education combined with pharmacotherapy
Number of subjects: 80
Study 25829103 — intervention group
Group type: COMPARATOR
Intervention: Routine counselling (Control)
Number of subjects: 80
Study 24134449 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine based ART
Number of subjects: 135
Study 24134449 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz based ART
Number of subjects: 135
Study 21138825 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide, 10 µg twice daily for 30 weeks
Number of subjects: 261
Study 21138825 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 30 weeks
Number of subjects: 261
Study 18822845 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0
Study 18822845 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination pharmacotherapy with antihypertensive drugs
Number of subjects: 0
Study 16847290 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg, uptitrated to 15 mg if necessary)
Number of subjects: 498
Study 16847290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498
Study 16847290 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 498
Study 12704354 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 1025
Study 12704354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1025
Study 10320243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (group MP)
Number of subjects: 0
Study 10320243 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo (group NS)
Number of subjects: 0
Study 9005421 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acromegaly (group A)
Number of subjects: 22
Study 9005421 — intervention group
Group type: COMPARATOR
Intervention: Normal glucose tolerance (group AT)
Number of subjects: 22
Study 9005421 — intervention group
Group type: COMPARATOR
Intervention: Impaired glucose tolerance (group AN)
Number of subjects: 22
Study 9005421 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (group K)
Number of subjects: 22
Study 1924643 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (single dose)
Number of subjects: 0
Study 1924643 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (single dose)
Number of subjects: 0
Study 1924643 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined effects of scopolamine and nicotine
Number of subjects: 0
Study 6354318 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG feedback
Number of subjects: 63
Study 6354318 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger temperature feedback
Number of subjects: 63
Study 6354318 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG plus finger temperature feedback
Number of subjects: 63
Study 6354318 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training
Number of subjects: 63
Study 6354318 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 63
Study 6354318 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 63
Study 30342296 — intervention group
Group type: EXPERIMENTAL
Intervention: East cohort (DES)
Number of subjects: 6503
Study 30342296 — intervention group
Group type: COMPARATOR
Intervention: West cohort (DES)
Number of subjects: 6503
Study 27426024 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga training (60-min classes weekly for six months)
Number of subjects: 12
Study 27426024 — intervention group
Group type: COMPARATOR
Intervention: Control (waiting list)
Number of subjects: 12
Study 24247413 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask (LM) method
Number of subjects: 140
Study 24247413 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal (ET) method
Number of subjects: 140
Study 22637363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling group
Number of subjects: 53
Study 22637363 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study 20565215 — intervention group
Group type: EXPERIMENTAL
Intervention: Reassignment of arbitrary cue-target pairings midway through the experiment
Number of subjects: 0
Study 20565215 — intervention group
Group type: COMPARATOR
Intervention: Control for effects of order of conditions or simple change of cue meaning
Number of subjects: 0
Study 20565215 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-pairing members of the same cue and target sets
Number of subjects: 0
Study 18992139 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental management arm
Number of subjects: 3000
Study 18992139 — intervention group
Group type: COMPARATOR
Intervention: EQ-5D health state classification
Number of subjects: 3000
Study 18992139 — intervention group
Group type: COMPARATOR
Intervention: Independent measure of distress
Number of subjects: 3000
Study 18992139 — intervention group
Group type: COMPARATOR
Intervention: Changes in EQ-5D severities
Number of subjects: 3000
Study 18992139 — intervention group
Group type: COMPARATOR
Intervention: Subject's perceived locus of control
Number of subjects: 3000
Study 18992139 — intervention group
Group type: COMPARATOR
Intervention: Age, educational attainment, ethnic origin, smoking behaviour
Number of subjects: 3000
Study 15969863 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa treatment
Number of subjects: 1010
Study 15969863 — intervention group
Group type: COMPARATOR
Intervention: Pre-treatment erythropoietin levels
Number of subjects: 1010
Study 15969863 — intervention group
Group type: EXPERIMENTAL
Intervention: Early response variables (change in haemoglobin after 4 weeks)
Number of subjects: 1010
Study 12870985 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric sulphate (FS) 15.5% solution applied for 15 seconds
Number of subjects: 70
Study 12870985 — intervention group
Group type: COMPARATOR
Intervention: Formocresol (FC) full strength (Buckley's formula) applied for 5 minutes
Number of subjects: 70
Study 10529851 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal epidural (CSE) analgesia
Number of subjects: 110
Study 7663659 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNase once daily
Number of subjects: 968
Study 7663659 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNase twice daily
Number of subjects: 968
Study 7663659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 968
Study 2025573 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin, cytosine arabinoside and thioguanine combination
Number of subjects: 156
Study 2025573 — intervention group
Group type: COMPARATOR
Intervention: Lower dosages of daunorubicin, cytosine arabinoside, etoposide and vindesine
Number of subjects: 156
Study 7249899 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 mm needle
Number of subjects: 97
Study 7249899 — intervention group
Group type: COMPARATOR
Intervention: 1.9 mm needle
Number of subjects: 97
Study 6543133 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric(III)‐dextrin complex
Number of subjects: 60
Study 6543133 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe(II)‐sulfate
Number of subjects: 60
Study 6543133 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe(II)‐fumarate with vitamins
Number of subjects: 60
Study 30199128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 268
Study 30199128 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy (SP)
Number of subjects: 268
Study 26136435 — intervention group
Group type: EXPERIMENTAL
Intervention: Orofacial Myofunctional Therapy (OMT)
Number of subjects: 22
Study 26136435 — intervention group
Group type: COMPARATOR
Intervention: Non-OMT (Control)
Number of subjects: 22
Study 24885811 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus additional rehabilitation service on Saturday
Number of subjects: 996
Study 24885811 — intervention group
Group type: COMPARATOR
Intervention: Usual care rehabilitation services from Monday to Friday
Number of subjects: 996
Study 22914255 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich olive oil (∼30 mg/day)
Number of subjects: 24
Study 20360461 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented communication input (AC-I)
Number of subjects: 68
Study 20360461 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented communication output (AC-O)
Number of subjects: 68
Study 20360461 — intervention group
Group type: COMPARATOR
Intervention: Spoken communication (SC)
Number of subjects: 68
Study 18561116 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromonics Tinnitus Treatment (customized neural stimulus)
Number of subjects: 0
Study 18561116 — intervention group
Group type: COMPARATOR
Intervention: Noise+Counseling (control group)
Number of subjects: 0
Study 18561116 — intervention group
Group type: COMPARATOR
Intervention: Counseling-Only (control group)
Number of subjects: 0
Study 18561116 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromonics Tinnitus Treatment
Number of subjects: 0
Study 18561116 — intervention group
Group type: COMPARATOR
Intervention: Noise+Counseling
Number of subjects: 0
Study 18561116 — intervention group
Group type: COMPARATOR
Intervention: Counseling-Only
Number of subjects: 0
Study 15809910 — intervention group
Group type: EXPERIMENTAL
Intervention: ORS with L-histidine (2.5 g/L)
Number of subjects: 126
Study 15809910 — intervention group
Group type: COMPARATOR
Intervention: ORS without L-histidine
Number of subjects: 126
Study 12398233 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (Ortho Tri-Cyclen: norgestimate and ethinylestradiol)
Number of subjects: 56
Study 12398233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 10605165 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine monotherapy (206.4 ± 44.4 mg/day)
Number of subjects: 47
Study 10605165 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine combined with carbamazepine (1208 ± 82.9 mg/day + 561.7 ± 76.8 mg/day)
Number of subjects: 47
Study 7489420 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen (FiO2 1.0)
Number of subjects: 25
Study 7489420 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O/O2 (FiO2 0.4)
Number of subjects: 25
Study 7489420 — intervention group
Group type: EXPERIMENTAL
Intervention: Air/O2 (FiO2 0.4)
Number of subjects: 25
Study 1659440 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg ml‐1 443C81
Number of subjects: 9
Study 1659440 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ml‐1 443C81
Number of subjects: 9
Study 1659440 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 9
Study 7037414 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol 40 mg b.d.
Number of subjects: 313
Study 7037414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 30273200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose IT naloxone (20 μg) and IT morphine (0.2 mg)
Number of subjects: 77
Study 30273200 — intervention group
Group type: COMPARATOR
Intervention: IT morphine (0.2 mg) alone
Number of subjects: 77
Study 31003657 — intervention group
Group type: EXPERIMENTAL
Intervention: Active video game intervention (twice a week for 45 minutes over eight weeks)
Number of subjects: 15
Study 31003657 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 15
Study 27663611 — intervention group
Group type: COMPARATOR
Intervention: Online first group (invited to complete the questionnaire online)
Number of subjects: 8795
Study 27663611 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice group (sent a paper questionnaire and offered a choice of completion method)
Number of subjects: 8795
Study 25542616 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyelid hygiene with neutral shampoo three times/day
Number of subjects: 45
Study 25542616 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral shampoo eyelid hygiene plus topical metronidazole gel 0.75% twice/day
Number of subjects: 45
Study 25542616 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral eyelid hygiene with shampoo plus neomycin 3.5% and polymyxin 10% antibiotic ointment with 0.5% dexamethasone 3 times/day
Number of subjects: 45
Study 23497438 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation activities by facilitators
Number of subjects: 151
Study 23497438 — intervention group
Group type: EXPERIMENTAL
Intervention: Robust evidence base
Number of subjects: 151
Study 23497438 — intervention group
Group type: EXPERIMENTAL
Intervention: Alignment of processes with existing initiatives
Number of subjects: 151
Study 23497438 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation context challenges
Number of subjects: 151
Study 21357957 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral simultaneous total knee replacement (TKR)
Number of subjects: 150
Study 21357957 — intervention group
Group type: COMPARATOR
Intervention: Unilateral total knee replacement (TKR)
Number of subjects: 150
Study 18288078 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (2 mg p.o.)
Number of subjects: 13
Study 18288078 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (0.25 mg p.o.)
Number of subjects: 13
Study 17063175 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0
Study 17063175 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 0
Study 17063175 — intervention group
Group type: COMPARATOR
Intervention: Control (age- and gender-matched healthy controls)
Number of subjects: 0
Study 12757769 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (OAC) with a target INR of 2.0-2.5 and aspirin 75 mg/day
Number of subjects: 0
Study 12757769 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 0
Study 11530046 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 48
Study 11530046 — intervention group
Group type: COMPARATOR
Intervention: Laser photocoagulation
Number of subjects: 48
Study 9432455 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Number of subjects: 0
Study 9432455 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help group
Number of subjects: 0
Study 9432455 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 0
Study 8235133 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support and health education intervention, including four to six visits during pregnancy, telephone hotline, consultation service, and health education materials.
Number of subjects: 620
Study 8235133 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 620
Study 3613407 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin free hemodialysis
Number of subjects: 29
Study 3613407 — intervention group
Group type: COMPARATOR
Intervention: Systemic heparinization, intermittent saline flushes, and constant saline infusions
Number of subjects: 29
Study 30368509 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily treatment with S-1
Number of subjects: 75
Study 30368509 — intervention group
Group type: COMPARATOR
Intervention: Alternate-day treatment with S-1
Number of subjects: 75
Study 26189608 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee ingestion and repeated bouts of low-intensity exercise (CR)
Number of subjects: 7
Study 26189608 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee ingestion and single bout of low-intensity exercise (CS)
Number of subjects: 7
Study 26189608 — intervention group
Group type: COMPARATOR
Intervention: Repeated bouts of low-intensity exercise with plain hot water (WR)
Number of subjects: 7
Study 26189608 — intervention group
Group type: COMPARATOR
Intervention: Single bout of low-intensity exercise with plain hot water (WS)
Number of subjects: 7
Study 26189608 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated bouts of low-intensity exercise with coffee (CR)
Number of subjects: 7